Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Can We Prevent KRAS-Driven Cancers Before They Start?
Research & Development Can We Prevent KRAS-Driven Cancers Before They Start?

The oncological landscape has fundamentally shifted as researchers move away from the defeatist "undruggable" label that once defined the KRAS gene for nearly four decades of clinical frustration and failure. Today, the medical community is pivoting from merely managing terminal, late-stage

Can MENTSH Revolutionize Type 2 Diabetes Treatment?
Research & Development Can MENTSH Revolutionize Type 2 Diabetes Treatment?

The longstanding biological assumption that the genetic blueprint for chronic metabolic diseases resides solely within the cell nucleus is being challenged by groundbreaking evidence involving the mitochondrial genome. For decades, clinicians and researchers have wrestled with the rising global

Control Bionics Secures FDA Registration for NeuroStrip
Tech & Innovation Control Bionics Secures FDA Registration for NeuroStrip

The convergence of human physiology and digital architecture has long been the holy grail of neurotechnology, yet the path to commercializing these systems is often blocked by regulatory hurdles and technical limitations that prevent seamless integration into daily life. Control Bionics Limited, an

Can Wave Life Sciences Redefine RNA-Based Medicine?
Research & Development Can Wave Life Sciences Redefine RNA-Based Medicine?

The pharmaceutical industry is currently witnessing a profound shift as genetic medicine transitions from theoretical promise into tangible, life-altering therapies for millions of patients. At the center of this transformation is Wave Life Sciences, a company that has strategically pivoted from

Macrophages Recruit Nerves to Fuel Triple-Negative Breast Cancer
Research & Development Macrophages Recruit Nerves to Fuel Triple-Negative Breast Cancer

The world of oncology is shifting its focus from the cancer cells themselves to the complex environment that sustains them. Ivan Kairatov, a biopharma expert with extensive experience in research and development, joins us to discuss a groundbreaking discovery from the University of Oklahoma. For

AIST Unveils New Fingerprinting Method for Biomanufacturing
Biotech & Bioprocessing AIST Unveils New Fingerprinting Method for Biomanufacturing

The National Institute of Advanced Industrial Science and Technology (AIST) has introduced a transformative analytical technique designed to redefine how manufacturers assess the quality and consistency of culture media. This innovation utilizes a sophisticated fingerprinting approach to capture

Gut Microbiome Regulates Nanomedicine Delivery to Tumors
Research & Development Gut Microbiome Regulates Nanomedicine Delivery to Tumors

The realization that trillions of microorganisms residing within the human digestive tract exert a profound influence on the systemic distribution of synthetic nanocarriers has completely revolutionized modern oncological strategies. Researchers have shifted their focus from merely optimizing the

Can Regenerative Medicine Reverse Parkinson’s Disease?
Biotech & Bioprocessing Can Regenerative Medicine Reverse Parkinson’s Disease?

The progressive loss of dopamine-producing neurons in the substantia nigra remains one of the most daunting challenges in modern neurology, affecting millions of lives worldwide today. Conventional treatments, such as levodopa, served as the gold standard for managing motor symptoms, yet these

How Does Medicare Support Your Virtual Doctor Visits?
Management & Regulatory How Does Medicare Support Your Virtual Doctor Visits?

The rapid transformation of healthcare delivery has fundamentally altered how millions of beneficiaries access essential medical services without leaving their homes. This evolution reflects a broader recognition that physical distance should not be a barrier to high-quality clinical outcomes or

Can AI Truly Reason in Drug Discovery and Development?
Tech & Innovation Can AI Truly Reason in Drug Discovery and Development?

The pharmaceutical industry is currently witnessing a profound shift where the initial excitement surrounding large language models is finally colliding with the cold, hard reality of clinical trial outcomes and biological complexity. While modern algorithms have become incredibly adept at

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later